InnovAge (INNV) Competitors $3.84 +0.04 (+1.05%) Closing price 07/25/2025 04:00 PM EasternExtended Trading$3.82 -0.02 (-0.52%) As of 07/25/2025 04:11 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock INNV vs. VCYT, ARDT, ADUS, PGNY, PACS, LFST, NHC, TDOC, GRAL, and VRDNShould you be buying InnovAge stock or one of its competitors? The main competitors of InnovAge include Veracyte (VCYT), Ardent Health (ARDT), Addus HomeCare (ADUS), Progyny (PGNY), PACS Group (PACS), LifeStance Health Group (LFST), National HealthCare (NHC), Teladoc Health (TDOC), GRAIL (GRAL), and Viridian Therapeutics (VRDN). These companies are all part of the "healthcare" industry. InnovAge vs. Its Competitors Veracyte Ardent Health Addus HomeCare Progyny PACS Group LifeStance Health Group National HealthCare Teladoc Health GRAIL Viridian Therapeutics InnovAge (NASDAQ:INNV) and Veracyte (NASDAQ:VCYT) are both small-cap medical companies, but which is the better investment? We will compare the two companies based on the strength of their institutional ownership, earnings, analyst recommendations, dividends, profitability, media sentiment, risk and valuation. Which has preferable earnings and valuation, INNV or VCYT? Veracyte has lower revenue, but higher earnings than InnovAge. InnovAge is trading at a lower price-to-earnings ratio than Veracyte, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioInnovAge$831.68M0.62-$21.34M-$0.23-16.70Veracyte$445.76M4.44$24.14M$0.4161.59 Is INNV or VCYT more profitable? Veracyte has a net margin of 7.13% compared to InnovAge's net margin of -3.75%. Veracyte's return on equity of 6.14% beat InnovAge's return on equity.Company Net Margins Return on Equity Return on Assets InnovAge-3.75% -11.91% -5.85% Veracyte 7.13%6.14%5.60% Which has more risk & volatility, INNV or VCYT? InnovAge has a beta of 0.51, meaning that its share price is 49% less volatile than the S&P 500. Comparatively, Veracyte has a beta of 2.07, meaning that its share price is 107% more volatile than the S&P 500. Does the media favor INNV or VCYT? In the previous week, Veracyte had 7 more articles in the media than InnovAge. MarketBeat recorded 9 mentions for Veracyte and 2 mentions for InnovAge. Veracyte's average media sentiment score of 1.08 beat InnovAge's score of 0.93 indicating that Veracyte is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment InnovAge 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Veracyte 4 Very Positive mention(s) 2 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Do insiders & institutionals have more ownership in INNV or VCYT? 12.3% of InnovAge shares are owned by institutional investors. 1.4% of InnovAge shares are owned by insiders. Comparatively, 1.4% of Veracyte shares are owned by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock is poised for long-term growth. Do analysts rate INNV or VCYT? InnovAge presently has a consensus price target of $5.00, indicating a potential upside of 30.21%. Veracyte has a consensus price target of $40.90, indicating a potential upside of 61.98%. Given Veracyte's stronger consensus rating and higher possible upside, analysts clearly believe Veracyte is more favorable than InnovAge.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score InnovAge 1 Sell rating(s) 1 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.50Veracyte 1 Sell rating(s) 1 Hold rating(s) 8 Buy rating(s) 0 Strong Buy rating(s) 2.70 SummaryVeracyte beats InnovAge on 13 of the 16 factors compared between the two stocks. Get InnovAge News Delivered to You Automatically Sign up to receive the latest news and ratings for INNV and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding INNV and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart INNV vs. The Competition Export to ExcelMetricInnovAgeMedical Services IndustryMedical SectorNASDAQ ExchangeMarket Cap$513.05M$7.30B$5.69B$9.50BDividend YieldN/A2.84%4.58%4.01%P/E Ratio-16.6925.2828.1020.05Price / Sales0.6242.19432.4490.07Price / CashN/A26.7436.2258.56Price / Book1.889.718.665.87Net Income-$21.34M$239.96M$3.25B$258.55M7 Day Performance-2.29%2.92%4.23%3.74%1 Month Performance-2.54%4.88%10.52%11.75%1 Year Performance-39.53%15.47%34.41%18.03% InnovAge Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)INNVInnovAge1.6521 of 5 stars$3.84+1.1%$5.00+30.2%-37.6%$513.05M$831.68M-16.692,350VCYTVeracyte3.6864 of 5 stars$26.65-1.6%$40.90+53.5%+6.3%$2.09B$445.76M65.00790News CoveragePositive NewsAnalyst UpgradeGap UpARDTArdent Health3.5501 of 5 stars$14.51+2.4%$20.67+42.4%-34.7%$2.08B$5.97B8.9024,900ADUSAddus HomeCare4.9631 of 5 stars$111.75+0.7%$142.57+27.6%-9.7%$2.06B$1.15B25.2349,703Positive NewsPGNYProgyny1.0866 of 5 stars$23.47+1.1%$24.09+2.6%-19.2%$2.01B$1.17B41.18310News CoveragePositive NewsAnalyst UpgradePACSPACS Group2.4646 of 5 stars$12.93+1.9%$34.29+165.3%-65.8%$1.97B$3.11B0.0032,433LFSTLifeStance Health Group2.907 of 5 stars$4.57+1.3%$8.50+86.0%-25.3%$1.78B$1.28B-45.7010,218Analyst ForecastNHCNational HealthCareN/A$103.17-0.1%N/A-26.2%$1.60B$1.37B12.9312,400High Trading VolumeTDOCTeladoc Health2.8987 of 5 stars$8.31-0.2%$9.65+16.2%-11.6%$1.46B$2.57B-1.405,500News CoverageUpcoming EarningsAnalyst ForecastGRALGRAIL0.6526 of 5 stars$40.18-1.4%$31.50-21.6%+154.2%$1.45B$125.60M-0.661,360Positive NewsVRDNViridian Therapeutics2.404 of 5 stars$17.14+0.6%$37.56+119.1%+5.8%$1.40B$300K-4.4550News CoveragePositive News Related Companies and Tools Related Companies VCYT Competitors ARDT Competitors ADUS Competitors PGNY Competitors PACS Competitors LFST Competitors NHC Competitors TDOC Competitors GRAL Competitors VRDN Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:INNV) was last updated on 7/26/2025 by MarketBeat.com Staff From Our PartnersMarket Panic: Trump Just Dropped a Bomb on Your Stockstock Market Panic: Trump Just Dropped a Bomb on Your Stocks The market is in freefall—and Trump's new tarif...American Alternative | SponsoredTrump's 2025 Economic Revolution Is Here Are Your Retirement Savings Ready?Time is short. Trump's reforms may be coming fast—and the financial system roller coaster may be a ride that y...Create New Advertiser | SponsoredINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | SponsoredCritical AI announcement set to ignite AI 2.0 I just put together an urgent new presentation that you need to see right away. In short: I believe we are...Timothy Sykes | SponsoredTrump’s betrayal exposed Trump’s Final Reset Inside the shocking plot to re-engineer America’s financial system…and why you need to ...Porter & Company | SponsoredHIDDEN IN THE BOOK OF GENESIS…“This land I will give to you…” — a 4,000-year-old line from Genesis may hold the key to unlocking a $150 tril...Paradigm Press | SponsoredBuffett to put 90% of his money in this one stock?CPA and CFA says you have WAY too many stocks - just buy these 3 After years working at the biggest accoun...Altimetry | Sponsored[Shocking New Report] U.S. Dollar To Crash?The "Death Spiral" Threatening Your Savings But this time, it's not just Dalio ringing the alarm bells…GoldCo Precious Metals | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding InnovAge Holding Corp. Please log in to your account or sign up in order to add this asset to your watchlist. Share InnovAge With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free INNV Stock Alerts